{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:38Z","timestamp":1792461038406,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Significance Statement<\/jats:title>\n                    <jats:p>This prespecified analysis of the SONAR trial in patients with type 2 diabetes and CKD demonstrated the early albuminuria reduction during an open-label, 6-week run-in period with atrasentan was associated with a reduced risk for long-term kidney outcomes in patients who continued atrasentan after randomization. But because the early albuminuria reduction also associated with long-term kidney outcomes in patients who transitioned from atrasentan to placebo at randomization, atrasentan\u2019s effect on the primary kidney outcome was consistent, regardless of the early albuminuria change, suggesting the early albuminuria response is not a causal predictor for atrasentan\u2019s nephroprotective effect. However, the variable UACR trajectory in the placebo arm, aspects of the SONAR trial design, day-to-day variability in albuminuria, and potential long-lasting effects of atrasentan may have contributed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether early reduction in albuminuria with atrasentan treatment predicts its long-term kidney-protective effect is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To assess the long-term effects on kidney outcomes of atrasentan versus placebo in the SONAR trial, we enrolled patients who had type 2 diabetes and CKD (stage 2\u20134) and a urinary albumin creatinine ratio (UACR) of 300\u20135000 mg\/g; participants were receiving maximum tolerated renin-angiotensin system inhibition. After 6 weeks exposure to 0.75 mg\/day atrasentan (enrichment period), participants were randomized (stratified by UACR response during enrichment, ranging from \u226460% to &gt;0%) to continue atrasentan or transition to placebo. Primary kidney outcome was a composite of sustained serum creatinine doubling or ESKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>UACR response to atrasentan during enrichment persisted throughout the double-blind treatment phase and predicted the primary kidney outcome, whereas UACR levels with placebo remained below pre-enrichment values in the two highest UACR response strata, and exceeded pre-enrichment values in the two lowest strata. As a result, early UACR response to atrasentan during enrichment was also associated with the primary kidney outcome during placebo. Accordingly, the predictive effect of early albuminuria changes during atrasentan was eliminated after placebo correction, leading to a consistent relative risk reduction for the primary kidney outcome with atrasentan compared with placebo, irrespective of the initial UACR response. The difference between atrasentan and placebo in UACR during double-blind treatment was also consistent across UACR response strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings do not support UACR response as a causal predictor of atrasentan\u2019s treatment effect. However, the variable trajectory in UACR with placebo, aspects of the trial design, day-to-day variability in albuminuria, and potential long-lasting effects of atrasentan may have contributed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.2021030391","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T14:45:40Z","timestamp":1632321940000},"page":"2900-2911","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial"],"prefix":"10.1681","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct01858532","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hiddo J. L.","family":"Heerspink","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"American Society Hypertension Comprehensive Hypertension Center, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[{"name":"National Medical Science and Nutrition Institute Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Fan","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Kohan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Makino","sequence":"additional","affiliation":[{"name":"Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[{"name":"Department of Medical Endocrinology, University of Copenhagen, Copenhagen, Denmark"},{"name":"Faculty of Health Science, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-7777","authenticated-orcid":false,"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf on the SONAR Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"B2-20240826","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"B3-20240826","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on \u2018KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease\u2019","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B6-20240826","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dom.12600","article-title":"Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B7-20240826","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the CREDENCE trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B8-20240826","doi-asserted-by":"crossref","first-page":"e016976","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: A post hoc analysis of the EMPA-REG OUTCOME Rrial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ki.2013.490","article-title":"Microalbuminuria: Target for renoprotective therapy PRO","volume":"86","author":"Roscioni","year":"2014","journal-title":"Kidney Int"},{"key":"B11-20240826","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B12-20240826","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"B13-20240826","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the Study Of Diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: An individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16-20240826","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bmj.308.6942.1499","article-title":"Regression towards the mean","volume":"308","author":"Bland","year":"1994","journal-title":"BMJ"},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bcp.13217","article-title":"Variability in response to albuminuria-lowering drugs: True or random?","volume":"83","author":"Petrykiv","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B21-20240826","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2021030391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:25:37Z","timestamp":1786130737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2021030391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2021030391","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2021-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}